Funding for this research was provided by:
Agentschap Innoveren en Ondernemen (IWT/VLAIO Innovation Mandate 130327 and 140568)
Vrije Universiteit Brussel (IOFPOC26)
Received: 17 August 2020
Accepted: 28 January 2021
First Online: 19 February 2021
Ethics approval and consent to participate
: The trial was approved by the Ethics Committee of Universitair Ziekenhuis Brussel (Vrije Universiteit Brussel) (BUN143201318000/143201628797). The data were collected and analyzed and the manuscript was prepared independently at Vrije Universiteit Brussel. All patients in the experimental arm provided specific written informed consent. All patients in the control arm provided written informed consent for retrospective use of their clinical data prior to their fertility treatment at Universitair Ziekenhuis Brussel.
: Not applicable.
: IVV and TA conducted all work related to the study while employees at Universitair Ziekenhuis Brussel. IVV reported employment by Fertiga NV since November 2019, TA reported employment by Fertiga NV since February 2020. JS was professor at Universitair Ziekenhuis Brussel until September 2019 and is currently Chief Medical Officer at Fertiga NV. EVH is Chief Commercial Officer and AR is Chief Executive Officer at Fertiga NV. EVH, AR and JS report board membership of Fertiga NV, hold stock in Fertiga NV, and receive service fees from Fertiga NV.MDV reports honoraria for lectures in the last 2 years from MSD and Ferring, outside the submitted work, as well as grant support from MSD. Other authors declared no conflicts of interest.